Article Text

COVID-19: time for paradigm shift in the nexus between local, national and global health
  1. Elisabeth Paul1,2,
  2. Garrett W Brown3,
  3. Valery Ridde4
  1. 1 School of Public Health, Université Libre de Bruxelles, Bruxelles, Belgium
  2. 2 Tax Institute, Liege University, Liege, Belgium
  3. 3 Global Health Theme, POLIS, University of Leeds, Leeds, West Yorkshire, UK
  4. 4 CEPED (IRD-Universités de Paris), INSERM, Institut de recherche pour le developpement, Paris, France
  1. Correspondence to Dr Elisabeth Paul; Elisabeth.Paul{at}ulb.ac.be

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Key messages

  • The COVID-19 pandemic has triggered unprecedented measures worldwide, which have often been adopted in an ‘emergency’ mode and are largely reactionary

  • Alternatively, COVID-19 needs to be appraised as part of a much bigger health picture, adopting a “systems approach” that enables interactions with other acknowledged and preventable health conditions, which often receive disproportionately low attention

  • To do so requires a paradigm shift in global health governance, from a specific reactional paradigm to a systemic, coordinated and preventive paradigm

  • It is necessary to adopt a holistic approach to health reflecting both a security approach and a health development approach, tackling upstream causes and determinants, aimed at helping populations reduce their individual risk factors and augment their natural immunity

  • Such preventive health policies must be tailored to local specificities and local environments, and health systems must be strengthened at the local level so as to be able to respond to population needs and expectations

  • The current crisis calls for a paradigm shift in public and global health policies; and in the in the nexus between local, national and global health policies and systems

Introduction

The WHO declared the novel coronavirus disease 2019 (COVID-19) an ‘emergency of international concern’ on 30 January 2020 and a pandemic on 11 March. According to WHO’s Situation Report - 79, as of 8 April 2020, the epidemic has caused 79 235 deaths worldwide.1 While it is seemingly nearing its end in China, where it was first reported, it is still on the rise in Europe, in the USA and in other parts of the world, including in many low-income and middle-income countries (LMICs). The pandemic has triggered unprecedented measures worldwide. Many countries have installed travel bans, confinement and lockdown policies. These responses have been adopted in an ‘emergency’ mode, and are largely reactionary, aimed at mitigating the spread of the disease while waiting for a specific cure and/or vaccine to be developed.

Here we do not want to underestimate the risks caused by the pandemic, nor to question the measures taken by the WHO and governments. But we would like to express our concerns regarding four COVID-19-related issues, and advocate for a ‘paradigm shift’—that is, a scientific revolution encompassing changes in the basic concepts and experimental practices of a scientific discipline 2—to prepare for future crises.

A shift in focus: COVID-19 in the broader global health picture

It is important to remember other acknowledged and preventable health conditions, when compared with the focus that COVID-19 has triggered at global and national levels. Respiratory diseases have been leading causes of death and disability in the world before COVID-19. It is estimated that, globally, four million people die prematurely from chronic respiratory disease each year; in particular, one million die annually from chronic obstructive pulmonary disease; pneumonia kills millions of people annually and is a leading cause of death among children under 5 years old; each year 1.4 million die from tuberculosis; and lung cancer kills 1.6 million people a year and is the deadliest cancer.3 The WHO estimates that seasonal influenza kills up to 650 000 people a year.4 In 2018, an estimated 405 000 people died of malaria.5 In 2017, about 295 000 women died during and following pregnancy and childbirth—that is approximately 810 women each day.6 In the USA alone, a lower limit of 210 000 deaths per year was associated with preventable harm in hospitals.7

Whereas infectious diseases seem to inspire the most terror among the public and policymakers, non-communicable diseases are responsible for almost 70% of all deaths.8 Depression affects 300 million people globally and is the leading cause of disability worldwide, and nearly 800 000 people die from suicide every year.9 The global boom in premature mortality and morbidity from non-communicable diseases has now reached a point where some have even suggested it to be a pandemic.10 Moreover, climate change (through increased heat waves and disasters) and atmospheric and environmental pollution are expected to increase deaths and injuries, especially in LMICs.11 In some debates, climate change has become more than a risk factor, with increasing calls for the WHO to declare it a public health emergency.12

From a public health perspective, COVID-19 needs to be appraised as part of a much bigger health picture. For instance, beyond the lethality and direct mortality rates of COVID-19, attention should be paid to the interaction with other pathogens, as well as to the more indirect effects of its mitigation measures.13 Indeed, the pandemic and its containment measures interact with, and impact on, other health conditions and will have system-wide effects, highlighting the importance of adopting a ‘systems approach’ to its resolution.14

A paradigm shift in global health governance

The global health community, national security agencies and all governments have known that a pandemic like COVID-19 was likely to come, yet global health policy has remained woefully unprepared nor fit-for-purpose. In 2015, the G7 members proclaimed that Ebola had been a ‘wake-up call’ for the need for better global cooperation. It was also recognised that antimicrobial resistance (AMR) threatened to kill 300 million people by 2050, thus demanding urgent action. Yet little has been done to address these existing global health governance shortcomings.15

For example, the lauded G7 and G20 response, the Global Health Security Agenda (https://ghsagenda.org/), continues to speak in the terms of costly ‘counter-measures’ versus prevention and health system strengthening. Moreover, the Pandemic Emergency Financing Facility (PEF) (https://www.worldbank.org/en/topic/pandemics/brief/pandemic-emergency-financing-facility), meant to deliver up to $500 million in epidemic assistance to curb expansion into a pandemic, sits idle as a complicated ‘loan mechanism’ at the World Bank, available to only a few countries (eg, China and India do not qualify for the money). There is also serious ambiguity about how the PEF intersects and/or complements the WHO’s Contingency Fund for Emergencies (CFE) (https://www.who.int/emergencies/funding/contingency-fund-for-emergencies). The CFE is available to more countries for more risks, and more quickly, but represents far less money than the PEF (which, in theory, should come after the CFE, if you happen to prequalify for the loan).16 The ‘One Health’ approach, which was meant to offer a more responsive research and policy agenda to combat zoonotic diseases, remains sluggish at best and underdeveloped in terms of including environmental factors, such as soil and water, which play a crucial part in AMR and other threats.17

In terms of pathogen monitoring and response, the 2005 International Health Regulations, which are meant ‘to help the international community and governments prevent and respond to acute public health risks that have the potential to cross borders and threaten people worldwide’,18 are not fully implemented by many countries due to limited financial resources and political will, and have been violated in response to the COVID-19 outbreak.19 What is more confounding is that many high-income countries like France have failed to fully implement the International Health Regulations, particularly in their overseas territories.16 In addition, other disease control mechanisms, like the WHO Global Influenza Surveillance and Response System (https://www.who.int/influenza/gisrs_laboratory/en/), remain inadequate and underfunded, with too few WHO laboratories and a market-based model where a global public good (pooled influenza knowledge) is turned into a private good (pharmaceutical profit), with historical inequities in terms of public health.20 Moreover, many countries, like China, are incentivised not to raise the epidemic alarm too soon due to fears of diminished direct foreign investment (like with severe acute respiratory syndrome, H7N9 and now COVID-19) and fears that the government will be perceived as weak.21

These conditions of incapacity at the international level are exacerbated by a weakened WHO, whose budget has been radically reduced and ring-fenced. For example, the WHO used to receive three-quarters of its financing from assessed contributions levied on members. However, a change to a zero real growth policy for its regular budget in the 1980s has meant it now only receives a quarter of its budget from member contributions. As a result, the WHO is dependent on extra-budgetary ring-fenced ‘pet project’ funding from donors to fill an increasingly shrinking budget.22 As the money flows to other multilateral health initiatives, the WHO’s authority dissipates, with numerous organisations like the Institute for Health Metrics and Evaluation, the Bill and Melinda Gates Foundation and Médecins Sans Frontières able to command greater epistemic authority,23 financial influence24 and response effectiveness.25 However, this expansion of initiatives creates a condition of policy fragmentation, which significantly weakens coordinated global public health.26 27

One real result of fragmentation of global health governance is an inefficient division of labour, where hundreds of actors such as the WHO, Global Fund, President’s Emergency Plan For AIDS Relief, United Nations Programme on HIV and AIDS, United States Agency for International Development, World Bank, the Gates Foundation and the Clinton Foundation (to name only a few) produce parallel programmes or bric-à-brac vertical health silos that have neither generated overall system strengthening in high burden countries nor allowed for effective global health policy.27 28 This creates two failures. First, contrary to sector-wide approaches,29 vertical ‘pet-project’ global initiatives often fail to promote sustainable long-term local health system strengthening, which is the best preventive defence for disease control (of all types, not just infectious diseases). Second, the global level is woefully unprepared for epidemics, since global policy has remained reactionary, symptom-based and dependent on vaccine discoveries without full appreciation of other upstream determinants of disease and access to those vaccines.

Given the state of global health governance and inadequate investments in health system strengthening—as well as the failure, by many actors, to adopt a ‘systems approach’ to problem resolution14—the spread and danger of COVID-19 is not surprising. What is required, we argue, is to shift global health policymaking from a specific reactional paradigm to a systemic, holistic and preventive paradigm. There is no doubt that this approach will require serious resources, governance reform and political will. Nevertheless, the global economic costs of COVID-19 have already reached into at least a trillion dollars.30 Thus, serious efforts to improve global and local health systems would be a small fraction of this cost, with a tried and true cost-saving philosophy that ‘an ounce of prevention is worth a pound of cure’.

Beyond the ‘Pasteurian paradigm’: a holistic view of health

The emergency responses to COVID-19 so far are based on the so-called ‘Pasteurian paradigm’, which states that each disease is due to one pathogen; thus, for each disease there is one cure, targeting the responsible pathogen. In this case, laboratories are racing to find the cure or the vaccine against COVID-19—a vaccine which will come too late for the current epidemic, and will have limited efficacy if the virus mutates in the coming months or years. Yet it is easy to see how the more pathogens there might be in the future (which there will be) the less this paradigm makes sense. Moreover, the Pasteurian paradigm has imposed its preferred research method—namely, randomised control trials that try to isolate one variable from all possible variables—as the gold standard of science, relegating other approaches as near charlatanism.

However, there is a multitude of evidence indicating that beyond a single pathogen, the development of a disease, as well as its outcome, is considerably affected by the physical and social parameters in which it operates, and that this is considerably affected by social, political, environmental and individual factors.31 32 This seems widely known by the public as far as chronic non-communicable diseases are concerned, but is also the case for infectious diseases, especially for emerging infections, in which the pathogenic role of social inequalities is recognised.33 Moreover, the traditional frontiers between communicable and non-communicable diseases are being blurred by evidence of ‘biosocial contagion’.34 In this light, the globalised world is now facing a ‘syndemic’—that is, a synergy of epidemics that ‘co­occur in time and place, interact with each other to produce complex sequelae, and share common underlying societal drivers’.35 COVID-19 is no exception, since its mortality rate varies significantly according to age, sex and comorbidities.36

As an alternative, we argue that it would be more effective, efficient and equitable to adopt a holistic approach to health. How to tackle the silent killers and how to prepare populations—including the most vulnerable37—against future epidemics should be on the top of national and global health policy and research agendas. This should reflect both a security approach (fighting symptomatic issues) and a health development approach (tackling upstream causes and determinants). In doing so, the objectives should not be merely be the response mode, but a more concerted effort to limit environmental factors, protect biodiversity,38 reduce social health inequities, strengthen local health systems for preventive health, help populations reduce their individual risk factors and augment their natural immunity—notably through various ‘healthy behaviours’ and diets that are proven to strengthen the general immune system.39–46 Like what recently took place in the field of evaluation of complex systems and policies,47 a ‘realist’ revolution of medical research is probably needed to help support this.

From global solutions to local adaptations

It is ultimately important that the resulting policies are not copy-pasted from other countries, but adapted to each context, and backed by strong local health systems. By definition, preventive health policies must be tailored to local specificities, including local environments, and health systems must be strengthened at the local level so as to be able to respond to a population’s needs and expectations. This is also the case for the response to COVID-19. Viruses and epidemics have always existed, and will always exist, and should be anticipated.48 49 Coronaviruses are a well-known family of viruses, and even if this one is particularly aggressive, its genome has been rapidly identified. The difference with this epidemic which is causing the semicollapse of health systems is that it has revealed a profound lack of national prevention and preparedness. In response to the epidemic, the most hit countries so far have faced a lack of equipment and critical care beds. In the UK and France, as just two examples, decades of austerity policies and an obsession with evaluating health facilities based on technical efficiency (ie, minimising inputs and increasing outputs) have considerably decreased the capacity of health systems to respond to above-average frequentation.50

The COVID-19 emergency responses of many states have revealed important inconsistencies. In many European countries, the authorities have adopted a one-size-fits-all policy and imposed the same measures everywhere. More worryingly, some governments—notably in Africa—have not performed their own adapted risk assessment before copy-pasting strategies from abroad.51 This is problematic, since it makes little sense to use a predictive model developed from a country where the median age is 47 and translate it to a country with a median age of 18, without adjusting the parameters. In addition, current policies fail to account for regional or transborder contextual parameters, where either more stringent or relaxed measures could be more suitable depending on geographical determinants. The universal lockdown of a whole country may not be necessary when there are only one or two epidemic outbreaks separated by hundreds of miles, especially if containment is quick and determined. What we suggest, in order to be effective, is that policies should fit each context and be adaptive at the territorial or ecosystem level, versus being unreflectively and uniformly bounded by national jurisdictions. This is the best way to not impose measures that are too coercive, which may face legal constraints and may be counterproductive, eroding public trust and cooperation.52 53

In the post-COVID-19 recovery phase, we hope the lessons learnt from local, national and global responses to this pandemic will foster support, by policymakers and by the public, for tailored policy responses that support stronger and more integrated local health systems.

Conclusion

In summary, the current crisis calls for a paradigm shift in public and global health policies. We will not be prepared for the next epidemic unless we take bold steps. First, global health policies should not be designed on a response mode to case-by-case threats, but should adopt a systems approach that can support a holistic picture of global disease burdens, risks and health conditions, as well as better consider the system-wide effects of adopted measures. Second, countering current fragmentation in global health governance will require a substantial shift in global health policymaking from a reactional paradigm to a systemic and preventive paradigm, with meaningful commitments to human health security. Third, there is a need to shift our focus from short-term curative policies based on the Pasteurian paradigm, to long-term preventive and promotional policies based on a holistic view of people’s health, which notably implies limiting environmental factors, reducing social health inequities, helping populations reduce their individual risk factors and augmenting their natural immunity. Lastly, such holistic, preventive policies must be adapted to local contexts and implemented through strong local health systems able to have the ‘cushion’ capacity to respond to emergencies.

Acknowledgments

We thank Seye Abimbola for inviting us to submit this commentary and for giving us critical suggestions for improvement, and Eric Muraille for advising on references on immunity.

References

Supplementary materials

  • This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Footnotes

  • EP and GWB are joint first authors.

  • Twitter @ValeryRidde

  • EP and GWB contributed equally.

  • Contributors EP and GB both had an initial idea for this paper and joined forces to arrive to this joint paper. They wrote the first draft and VR contributed to improving it. All authors contributed to the development of ideas, commenting on drafts and approved the final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests EP and VR have conducted consultations for various international and donor agencies. GB and VR have received funding from several research funding agencies. However, this article has been written in total independence of these contracts.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

  • Data availability statement There are no data in this work.